Quoin Pharmaceuticals Ltd DRC
$ 4.43
-2.85%
03 Jun - close price
- Market Cap 9,158,400 USD
- Current Price $ 4.43
- High / Low $ 4.82 / 4.11
- Stock P/E N/A
- Book Value 8.76
- EPS -10.07
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.76 %
- ROE -2.31 %
- 52 Week High 23.50
- 52 Week Low 4.11
About
Quoin Pharmaceuticals Ltd (QNRX) is a biotechnology firm focused on developing innovative therapeutics for rare diseases and unmet medical needs. By utilizing advanced drug delivery technologies, the company enhances the efficacy and safety of existing pharmaceuticals, positioning itself as a key player in the specialty pharmaceuticals sector. Quoin's robust pipeline includes promising therapies aimed at critical health conditions, highlighting its potential for substantial clinical advancements and market impact. The company is dedicated to creating value for both patients and investors through strategic collaborations and cutting-edge research initiatives.
Analyst Target Price
$29.75
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-03-26 | 2025-11-06 | 2025-08-07 | 2025-05-13 | 2025-03-13 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-13 | 2023-11-08 | 2023-08-02 |
| Reported EPS | -1.77 | -1.74 | -6.7 | -6.28 | -6.5 | -0.2781 | -16.45 | -13.67 | -38.62 | -2.08 | -68.25 | -73.48 |
| Estimated EPS | -2.26 | -4.02 | -1.92 | -6.83 | -4.2 | -0.43 | -15.4 | -20.3 | -14.35 | -2.31 | -95.32 | -96.6 |
| Surprise | 0.49 | 2.28 | -4.78 | 0.55 | -2.3 | 0.1519 | -1.05 | 6.63 | -24.27 | 0.23 | 27.07 | 23.12 |
| Surprise Percentage | 21.6814% | 56.7164% | -248.9583% | 8.0527% | -54.7619% | 35.3256% | -6.8182% | 32.6601% | -169.1289% | 9.9567% | 28.3991% | 23.9337% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: QNRX
2026-06-02 21:10:21
Millennium affiliates and Israel A. Englander have reported a shared beneficial ownership of 3,850,385 ordinary shares, representing 5.5% of Quoin Pharmaceuticals Ltd. (QNRX). This disclosure was made via a Schedule 13G SEC filing, indicating a passive investment stake rather than a controlling interest. The filing confirms a joint filing agreement dated June 1, 2026, among Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander.
2026-06-02 13:39:58
Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose after the company filed an Investigational New Drug (IND) application for QRX003 to treat Peeling Skin Syndrome (PSS), a rare skin disorder with no current treatment. This marks the first IND application for PSS, and Quoin plans to start a Phase 2 clinical study in late 2026. The submission is supported by positive clinical observations from an ongoing study, and QRX003 has been well-tolerated.
2026-06-02 12:39:58
Quoin Pharmaceuticals has submitted an Investigational New Drug (IND) application to the FDA for QRX003 to treat Peeling Skin Syndrome (PSS), a rare genodermatosis with no current approved treatment. The submission follows promising clinical observations in an investigator-led pediatric study where QRX003 showed significant improvements over 15 months and was well-tolerated. Quoin plans to initiate a Phase 2 study in the second half of 2026, recruiting 6-8 patients in the US and Europe, further expanding QRX003's development into a second rare dermatologic indication.
2026-06-02 12:39:58
Quoin Pharmaceuticals has submitted an Investigational New Drug (IND) application to the FDA for QRX003, intended for Peeling Skin Syndrome (PSS), a condition currently without approved treatments. This application is supported by over 15 months of positive clinical observations in a pediatric patient, showing significant improvements and no adverse events. Pending FDA review, Quoin plans to initiate a Phase 2 trial in the second half of 2026 for 6-8 pediatric and adult PSS patients in the US and Europe, establishing PSS as a second indication for QRX003 alongside Netherton Syndrome.
2026-06-02 09:39:58
Quoin Pharmaceuticals Ltd. has updated its resale prospectus to replace Point72 Associates, LLC with SILV Fund Ltd. in the selling shareholders table. This change reflects the transfer of warrants to purchase 909,090 American Depositary Shares (ADSs). The total number of ADSs registered for resale (10,045,455) and other prospectus terms remain unchanged.
2026-06-01 03:39:20
This article focuses on the number of shareholders for Quoin Pharmaceuticals. Ltd Sponsored ADR (FWB:2EB0). It presents a financial data page from TradingView for the company, indicating various financial metrics and information channels. The content structure suggests that the specific shareholder data can be accessed by selecting a period value on the platform.
